A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension.
Phase of Trial: Phase III
Latest Information Update: 03 May 2014
At a glance
- Drugs Taranabant (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2010 104-week results published in the International Journal of Obesity.
- 05 May 2009 Trial phase changed from II to III as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History